ACE Report Cover
TKA: No effect of fibrin sealant on reducing blood loss and functional recovery
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Lingua
Download Download Download
Scaricare
Cite this Report Cite this Report Cite this Report
Citare
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Preferiti
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Lingua
Download Download Download
Scaricare
Cite this Report Cite this Report Cite this Report
Citare
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Preferiti
ARTHROPLASTY
TKA: No effect of fibrin sealant on reducing blood loss and functional recovery .

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2013;1(8):6 Acta Orthop. 2013 Apr;84(2):153-8. doi: 10.3109/17453674.2013.769082. Epub 2013 Jan 25

24 patients (48 knees) undergoing simultaneous bilateral total knee arthroplasty (TKA) had their knees 1:1 randomized to receive an intraoperative application of either fibrin sealant or saline. The purpose was to determine the adjuvant effect of fibrin sealant on postoperative blood loss in patients already treated with preoperative tranexamic acid and tourniquet use. Blood loss was calculated 24 hours following surgery, and patients were assessed for functional recovery up to 21 days postoperatively. The findings indicated that there was no decrease in blood loss in knees treated with fibrin sealant, and that pain, swelling, range of motion, and isokinetic strength was similar between knees, regardless of the application of fibrin sealant or saline.


Dettagli sul finanziamento della pubblicazione +
Finanziamento:
Industry funded
Sponsor:
Johnson and Johnson Medical Ltd.
Conflitti:
None disclosed

Rischio di pregiudizio

8,5/10

Criteri di segnalazione

17/20

Indice di fragilità

N/A

Was the allocation sequence adequately generated?

Was allocation adequately concealed?

Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?

Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?

Blinding Patients: Was knowledge of the allocated interventions adequately prevented?

Was loss to follow-up (missing outcome data) infrequent?

Are reports of the study free of suggestion of selective outcome reporting?

Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?

Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?

Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?

Sì = 1

Incerto = 0,5

Non rilevante = 0

No = 0

La valutazione dei criteri di segnalazione valuta la trasparenza con cui gli autori riportano le caratteristiche metodologiche e sperimentali dello studio all'interno della pubblicazione. La valutazione è suddivisa in cinque categorie che vengono presentate di seguito.

4/4

Randomization

3/4

Outcome Measurements

2/4

Inclusion / Exclusion

4/4

Therapy Description

4/4

Statistics

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

L'Indice di Fragilità è uno strumento che aiuta l'interpretazione dei risultati significativi, fornendo una misura della forza di un risultato. L'Indice di Fragilità rappresenta il numero di eventi consecutivi che devono essere aggiunti a un risultato dicotomico per rendere il risultato non più significativo. Un numero piccolo rappresenta un risultato più debole, mentre un numero grande rappresenta un risultato più forte.

Perché questo studio era necessario ora?

Postoperative blood loss following total knee arthroplasty (TKA) may be associated with significant morbidity and impaired functional recovery. There have been many developments in stemming blood loss following surgery, one of which is a topical application of fibrin sealant. While the hemostatic agent has been investigated in prior studies, there is limited evidence of its effect as an adjunct to other blood loss regimens (ie. tranexamic acid, intramedullary femoral canal plugging), as well as its effect on functional recovery.

Qual era la domanda di ricerca principale?

What is the effect of adjuvant fibrin sealant on postoperative blood loss and early functional recovery following total knee arthroplasty, with blood loss measured within the first 24 postoperative hours and function assessed up to 21 days postoperatively?

Caratteristiche dello studio +
Population:
24 patients (n=48 knees) undergoing simultaneous bilateral total knee arthroplasty. All patients were given preoperative cefuroxime (1.5g intravenously) and tranexamic acid (0.5g 10 min prior to tourniquet inflation (100mmHg above systolic pressure) on the first knee, followed by 0.5g after deflation and before inflation on the second knee), and were operated on with a medial parapatellar approach. Closure of the femoral canal was achieved with an autologous bone plug, and one intra-articular drain (passive) was installed in each knee. Patients either received AGC or Vanguard ROCC (Biomet) prostheses. (Mean age: 65 years)
Intervention:
Fibrin sealant group: After implantation of the knee prosthesis, and while the tourniquet was still inflated, 10mL of fibrin sealant (Evicel) was sprayed onto all instrumented cut surfaces and soft tissues. (n=24 knees)
Comparison:
Control group: After implantation of the knee prosthesis, and while the tourniquet was still inflated, 10mL of saline was sprayed onto all instrumented cut surfaces and soft tissues. (n=24 knees)
Outcomes:
Primary outcome was blood loss within the first 24h postoperatively, measured by drain output. Secondary outcomes included pain on a visual analog scale (VAS), knee swelling measured by knee circumference (1cm proximal to patella), knee range of motion (ROM) using a goniometer, and isometric knee strength.
Methods:
RCT, Double-blind, Placebo-controlled, Single-centre
Time:
Blood loss was measured at 24h postoperatively. Knee pain and swelling were assessed daily until postoperative day (POD) 3, then again at POD 7 and 21. ROM and strength assessment was conducted at POD 3, 7, and 21.
Quali erano i risultati importanti?
  • Mean blood loss calculated from drains at 24h postoperatively was 582mL (SD 328mL) for knees allocated to the fibrin sealant and 576mL (SD 289mL) in knees treated with saline (p=0.9).
  • There was no significant difference in pain between groups either at rest or during flexion at any time-point (all p>0.05).
  • Knee swelling did not significantly differ between groups at any assessment (p>0.05).
  • ROM assessment of both flexion and extension were observed to be similar between groups at each time point, with no significant differences being observed (all P>0.05).
  • Isometric knee strength was similarly reduced from baseline at day 3 assessment in both groups, with gradual recovery. Recovery by day 21 was still lower that preoperative values. There were no significant differences between groups at any of the assessments (all P>0.05).
Che cosa devo ricordare di più?

The use of the fibrin sealant, Evicel, in total knee arthroplasty did not reduce blood loss, nor promote any benefit in functional recovery when compared to placebo treatment with saline in the contralateral knee.

Come influenzerà l'assistenza ai miei pazienti?

The results of the present study do not support the application of adjuvant fibrin sealant as a means to stem postoperative blood loss following total knee arthroplasty. However, there was concern that hyperemia caused by the deflation of the tourniquet may have flushed out the fibrin sealant prior to eliciting any potential effect. It may be worthwhile to determine if there is an effect of Evicel in the absence of tourniquet use.

DISCLAIMER

Il contenuto di questa pagina è solo a scopo informativo e non intende sostituire la consulenza, la diagnosi o il trattamento medico professionale. Se ha bisogno di cure mediche, si rivolga sempre al suo medico o al pronto soccorso più vicino. Le opinioni, le convinzioni e i punti di vista espressi dalle persone sui contenuti presenti in questa pagina non riflettono le opinioni, le convinzioni e i punti di vista di OrthoEvidence.

0 di 4 articoli mensili GRATUITI sbloccati
Ha raggiunto il suo limite di 4 visualizzazioni di articoli gratuiti questo mese

Accesso a OrthoEvidence a soli 1,99 dollari a settimana.

Rimanga in contatto con le ultime prove. Può disdire in qualsiasi momento.
  • Valutazioni critiche dei più recenti studi randomizzati controllati ad alto impatto e delle revisioni sistematiche in ortopedia.
  • Accesso ai contenuti del podcast OrthoEvidence, tra cui collaborazioni con il Journal of Bone and Joint Surgery, interviste con chirurghi di fama internazionale e tavole rotonde su notizie e argomenti ortopedici.
  • Abbonamento a The Pulse, una newsletter bisettimanale basata sulle evidenze scientifiche, progettata per aiutarla a prendere decisioni cliniche migliori.
Upgrade
Close Dialog
Bentornato!
Ha dimenticato la password?
Inizi la sua prova gratuita oggi stesso!

Il suo account sarà affiliato a
e includerà l'accesso gratuito a OrthoEvidence


O
Ha dimenticato la password?

O
Controlli la sua e-mail

Se esiste un account con l'indirizzo e-mail fornito, le verrà inviata un'e-mail di reimpostazione della password. Se non vede l'e-mail, controlli la cartella spam o posta indesiderata.

Per ulteriore assistenza, contatti il nostro team di supporto.

Effettui il login per abilitare questa funzione

Per accedere a questa funzione, deve essere collegato ad un account OrthoEvidence attivo. Effettui il login o crei un account di prova GRATUITO.

Tradurre il Rapporto ACE

OrthoEvidence utilizza un servizio di traduzione di terze parti per rendere i contenuti accessibili in più lingue. Si prega di notare che, sebbene venga fatto ogni sforzo per garantire l'accuratezza, le traduzioni potrebbero non essere sempre perfette.

Come citare questo documento ACE Report

OrthoEvidence. TKA: No effect of fibrin sealant on reducing blood loss and functional recovery. OE Journal. 2013;1(8):6. Available from: https://myorthoevidence.com/AceReport/Show/tka-no-effect-of-fibrin-sealant-on-reducing-blood-loss-and-functional-recovery

Copiare la citazione
Effettui il login per abilitare questa funzione

Per accedere a questa funzione, deve essere collegato ad un account OrthoEvidence attivo. Effettui il login o crei un account di prova GRATUITO.

Funzionalità per i membri Premium

Per accedere a questa funzione, deve essere collegato ad un account OrthoEvidence Premium.

Condividi questo articolo ACE Report